Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project

[1]  S. de Lusignan,et al.  ADVANCE database characterisation and fit for purpose assessment for multi-country studies on the coverage, benefits and risks of pertussis vaccinations. , 2020, Vaccine.

[2]  R. Gini,et al.  Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project. , 2019, Vaccine.

[3]  S. de Lusignan,et al.  Why we need more collaboration in Europe to enhance post-marketing surveillance of vaccines. , 2019, Vaccine.

[4]  B. Carleton,et al.  Incidence rates of narcolepsy diagnoses in Taiwan, Canada, and Europe: The use of statistical simulation to evaluate methods for the rapid assessment of potential safety issues on a population level in the SOMNIA study , 2018, PloS one.

[5]  M. Sturkenboom,et al.  Methodology for computing the burden of disease of adverse events following immunization , 2018, Pharmacoepidemiology and drug safety.

[6]  S. K. Shukla,et al.  Infections, genetic and environmental factors in pathogenesis of autoimmune thyroid diseases. , 2018, Microbial pathogenesis.

[7]  M. Sturkenboom,et al.  CodeMapper: semiautomatic coding of case definitions. A contribution from the ADVANCE project , 2017, Pharmacoepidemiology and drug safety.

[8]  F. Voller,et al.  Epidemiology of Kawasaki disease in Italy: surveillance from national hospitalization records , 2017, European Journal of Pediatrics.

[9]  M. Kleinewietfeld,et al.  Environmental factors in autoimmune diseases and their role in multiple sclerosis , 2016, Cellular and Molecular Life Sciences.

[10]  J. Sundquist,et al.  Gender-specific incidence of autoimmune diseases from national registers. , 2016, Journal of autoimmunity.

[11]  G. Hall,et al.  Kawasaki disease incidence in children and adolescents: an observational study in primary care. , 2016, The British journal of general practice : the journal of the Royal College of General Practitioners.

[12]  V. Bauchau,et al.  Pharmacoepidemiological considerations in observed‐to‐expected analyses for vaccines† , 2015, Pharmacoepidemiology and drug safety.

[13]  S. Cotter,et al.  Investigation of an association between onset of narcolepsy and vaccination with pandemic influenza vaccine, Ireland April 2009-December 2010. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[14]  P. Villoslada,et al.  Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008–2012 , 2014, Journal of Neurology.

[15]  Michael Nguyen,et al.  Post-licensure rapid immunization safety monitoring program (PRISM) data characterization. , 2013, Vaccine.

[16]  Sebastiaan Overeem,et al.  The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. , 2013, Vaccine.

[17]  M. Jit,et al.  The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England. , 2012, Vaccine.

[18]  J. Slattery,et al.  Safety monitoring of Influenza A/H1N1 pandemic vaccines in EudraVigilance. , 2011, Vaccine.

[19]  S. Black,et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines , 2009, The Lancet.